Nanobiotix Engaging with Investors in Upcoming Conferences
Nanobiotix, a pioneering biotechnology company committed to advancing cancer treatments through innovative nanoparticle-based therapies, is preparing for a series of impactful investor conferences. With a vision of transforming the treatment landscape for cancer patients, the company is set to showcase its advancements in expanding therapeutic possibilities. Management is eager to engage in conversations that can shape the future of healthcare.
Key Events on the Conference Agenda
Guggenheim SMID Cap Biotech Conference
On February 6, 2025, at 1 PM EST, Bart van Rhijn, the Chief Financial & Business Officer, will represent Nanobiotix at the Guggenheim SMID Cap Biotech Conference in New York City. This conference serves as a crucial platform for biotech firms to connect with investors and stakeholders who share a commitment to advancing medical science.
Leerink Global Healthcare Conference
Following that, on March 12, 2025, at 10:40 PM EST, Laurent Levy, the Chief Executive Officer, alongside Bart van Rhijn, will participate in the Leerink Global Healthcare Conference held in Miami, Florida. This dual presentation is poised to highlight the strategic direction and innovations that Nanobiotix is championing in the field of oncology.
Interactive Webcast for Investor Engagement
The dialogues during these conferences will be accessible through live webcasts via the events page on the Company's website, ensuring that interested parties can participate in real-time. Additionally, recordings of these sessions will be made available for those who wish to revisit the insights shared during the events.
About Nanobiotix and Its Innovative Approach
Founded in 2003 and listed on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix is on the forefront of developing unique therapeutic solutions aimed at significantly improving patient outcomes globally. The company's focus includes three major nanotechnology platforms which tackle oncology, bioavailability, and disorders impacting the central nervous system.
Headquartered in Paris, with operations extending to Cambridge, Massachusetts, Nanobiotix is committed to a philosophy of innovation through science. The team aims to push boundaries and explore new frontiers in treatment efficacy for serious diseases, including cancer.
A Commitment to Innovation and Equity
As a holder of over 25 patent families related to its cutting-edge technologies, Nanobiotix continues to strive toward making transformative changes in health care. The company believes in the potential for their discoveries to redefine how major diseases are treated, expanding access and effectiveness of therapies for patients worldwide.
For those seeking further information about the exciting developments at Nanobiotix, additional details can be found on the company’s official website, where updates on research, conferences, and breakthroughs are regularly posted.
Frequently Asked Questions
What is Nanobiotix known for?
Nanobiotix specializes in innovative nanoparticle-based therapies aimed at enhancing treatment options for cancer patients.
When will the upcoming conferences take place?
The Guggenheim SMID Cap Biotech Conference is scheduled for February 6, 2025, and the Leerink Global Healthcare Conference on March 12, 2025.
Who will represent Nanobiotix at these conferences?
Bart van Rhijn and Laurent Levy will be the key presenters at the upcoming conferences.
How can I watch the conference presentations?
The presentations will be available via a live webcast on the company’s events page, with recordings accessible afterward.
Where is Nanobiotix located?
Nanobiotix is headquartered in Paris, France, with a subsidiary in Cambridge, Massachusetts, among other locations.
